Communiqués Milestone Pharmaceuticals Inc.

Actions

MIST

CA59935V1076

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
0,9801 ^USD	-6,66%		-18,32%	-51,48%

03/09	Milestone Pharmaceuticals reçoit l'approbation de la NMPA pour le spray nasal etripamil contre la TSVP en Chine	CI
27/08	Milestone Pharmaceuticals présente des données sur l'impact de la tachycardie paroxystique supraventriculaire (TPSV) sur la vie quotidienne et la qualité de vie des patients entre les épisodes au Congrès de l'ESC 2026	CI

Communiqués

03/09	Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States	AQ
02/09	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences	AQ
28/08	Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia on Patients Daily Lives and Quality of Life between Episodes	AQ
27/08	Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes	AQ
24/08	Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)	AQ
21/08	Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)	AQ
12/08	Milestone Pharmaceuticals: Q2 Earnings Snapshot	AQ
12/08	Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
04/08	Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026	AQ
06/07	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 2, 2026	AQ
06/07	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
03/07	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
14/05	Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ	AQ
13/05	Milestone Pharmaceuticals: Q1 Earnings Snapshot	AQ
13/05	Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update	AQ
06/05	Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026	AQ
13/04	Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST Nasal Spray in Patients with PSVT	AQ
13/04	Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST (etripamil) Nasal Spray in Patients with PSVT	AQ
10/04	Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT	AQ
07/04	Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference	AQ
02/04	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
31/03	Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies	AQ
20/03	Milestone Pharmaceuticals: Q4 Earnings Snapshot	AQ
20/03	Milestone Pharmaceuticals : Annual Report for Fiscal Year Ending 12-31, 2025 (Form 10-K)	PU
16/03	Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session	AQ